Inherited muscle disorders form a heterogeneous group characterized by different patterns of muscle weakness. Some have a unique phenotype allowing a diagnostic with single-gene testing. Others, like the limb-girdle weakness pattern, do not have a specific gestalt and are associated with numerous genes. Muscle biopsy has long been considered the gold standard test but is not without limitations. Indeed, it is particularly invasive, and specific antibodies are not available for all proteins encoded by causal genes.^[@R1]^ Therefore, genetic testing is increasingly used and can be obtained in a noninvasive manner. Across different countries such as Canada, the United States, China, Korea, Germany, the United Kingdom, Egypt, Poland, Australia, and Japan, gene panel sequencing has a yield varying from 16% to 65%,^[@R2][@R3][@R7]^ depending on subgroups of patients\' selection, whereas exome sequencing has a yield in between 13% and 69%^[@R8][@R9][@R15]^ in different settings. Its superiority over gene panel, in diagnosing common etiologies, remains to be quantified.

Reaching a molecular diagnosis is becoming increasingly important for patients management, including participation in clinical trials and treatment eligibility, such as enzyme replacement in Pompe disease.^[@R16]^

Here, we report on the diagnostic yield of an 89-gene panel in a large cohort of Canadian patients with suspected muscle disorders from outpatient clinics, and we compare the diagnostic yield of gene panel and exome sequencing approaches in a single-center cohort.

Methods {#s1}
=======

Recruitment of patients {#s1-1}
-----------------------

We analyzed DNA samples of 1,236 patients (201 children and 1,035 adults; 574 females and 662 males) seen by 187 physicians in outpatient clinics (general neurology, specialized neuromuscular, genetics, physiatry, and general practice) at 61 locations across Canada (figure e-1, [links.lww.com/NXG/A233](http://links.lww.com/NXG/A233)). DNA samples were extracted from blood samples. The clinical gene panel test was performed in the laboratory of Sherbrooke Genomic Medicine (a not-for-profit organization), and the cost of the test was covered by a special program with financial support from Sanofi Genzyme. To be eligible, patients were required to show any type of muscle weakness or symptoms suggestive of muscle involvement (i.e., myalgia, rhabdomyolysis, exercise intolerance, and unexplained respiratory insufficiency), at least 1 abnormal laboratory finding suggestive of muscle involvement (plasma creatine kinase \[CK\], EMG, muscle biopsy, or MRI), and no reported diagnosis. Demographics and clinical information were obtained from the laboratory requisition, which included specific sections for muscle phenotype, respiratory symptoms, cardiac anomalies, and clinical laboratory results. Age at onset and previous genetic testing were not systematically mentioned. Furthermore, complete muscle biopsy reports were not available to us. Respiratory and cardiac phenotypes were described in 83.4% and 71.0% of patients, respectively. Cardiac anomalies included hypertrophic or dilated cardiomyopathies and arrhythmias for 82.2% of patients and were unspecified for the remaining. CK, EMG, muscle biopsy, and MRI results were available for 89.5%, 81.6%, 32.7%, and 11.7% of patients, respectively. In addition, 46 patients were recruited using the above-mentioned criteria from neuromuscular and genetics outpatient clinics at Centre Hospitalier Universitaire de Sherbrooke. There was no overlap with the 1,236 patients above. Fifty-four percent had single gene or panel testing prior performing exome sequencing. DNA was than analyzed by exome sequencing on a research basis, following genetic counseling. Because patients come from outpatient clinics, follow-up was made by treating physicians.

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

The study was approved by the institutional ethics review board at Université de Sherbrooke (project \#\#MP-31-2013-533, 12-208). All participants (or their legal guardians) who underwent exome sequencing provided participants\' written consent.

Gene panel sequencing {#s1-3}
---------------------

We designed a panel of 89 genes targeting diverse patterns of muscle weakness that could be encountered in outpatient clinics and covering the following groups of disorders: limb-girdle muscular dystrophies (LGMDs), congenital muscular dystrophies, congenital myasthenic syndromes, nemaline myopathy, myofibrillar myopathy, centronuclear myopathy, collagen VI--related myopathies, inclusion myopathies, metabolic myopathies, rigid spine syndromes, and scapuloperoneal syndromes. The list of the 89 genes is provided in table e-1 ([links.lww.com/NXG/A234](http://links.lww.com/NXG/A234)) and supplementary file e-1 ([links.lww.com/NXG/A240](http://links.lww.com/NXG/A240)). For each patient, DNA libraries were prepared following a standard protocol (Kapa Biosystems, Roche, MA), followed by target enrichment (Seq Cap EZ-Custom) and sequenced on a MiSeq (Illumina, San Diego, CA) or a NextSeq (Illumina) with a 150-bp paired-end protocol. A total of 383 and 853 patients were sequenced on MiSeq and NextSeq, respectively.

Exome sequencing {#s1-4}
----------------

Exome sequencing was performed as previously described.^[@R8]^ Briefly, it was performed at the McGill University and Génome Québec Innovation Centre (Montreal, Canada) or Fulgent (Temple City, CA). DNA libraries were prepared for each patient (TruSeq; Illumina), followed by target enrichment (Agilent SureSelect All Exon kit v4 or v5 or Illumina Truseq Exome) and sequenced on a HiSeq 2000 (Illumina) with a 100-bp paired-end protocol or HiSeq 4000 (Illumina) with a 150-bp paired-end protocol.

Bioinformatics and statistical analysis {#s1-5}
---------------------------------------

We analyzed the sequencing data using a Linux-based bioinformatics pipeline based on the one developed by the McGill University and Génome Québec Innovation Centre ([bitbucket.org/mugqic/mugqic_pipelines](https://bitbucket.org/mugqic/mugqic_pipelines)) as previously described.^[@R6]^ Briefly, (1) raw reads were trimmed using Trimmomatic^[@R17]^ (version 0.32); (2) sequence alignment was performed with Burrows-Wheeler Aligner^[@R18]^ (version 0.7.10); (3) genetic variants (single nucleotide polymorphisms and indels) were called with the HaplotypeCaller using the Genome Analysis Toolkit^[@R19]^ (version 3.2.2) with prior local realignment, base recalibration, and removal of polymerase chain reaction (PCR) duplicates using Picard (version 1.123, [broad](http://broad) institute.github.io/picard/); (4) gene annotation was performed with SnpEff/SnpSift^[@R20]^ (versions 3.6 and 4.2, including SIFT, Polyphen2, and MutationTaster predictions) with an additional in-house script to annotate variants present in the ClinVar^[@R21]^ database; and (5) a filtering process removed variants outside targeted sequences, with population frequency \>1% (dbSNP 138 and ExAC 0.3^[@R22]^) and genotype quality less than Q30. Coverage depth was calculated using BED Tools.^[@R23]^ Filtered variant lists obtained from the bioinformatics pipeline were then interpreted with an in-house script and manual revision. For both gene panel and exome sequencing, deletion and duplication analysis were performed using the CoNVaDING software^[@R24]^ and manual review of binary alignment map files before quantitative PCR confirmation using Taqman Copy Number Assay (Thermo Fisher Scientific, Montreal, Canada). Variants were revised manually and were reported according to the American College of Medical Genetics and Genomics guidelines.^[@R25]^ For exome sequencing, a subset of 89 genes (included in the gene panel) was analyzed before the whole-exome data. Variants of uncertain significance (VUS) were reported only if related to the patient\'s phenotype. Sanger sequencing confirmation was only performed if any of the following criteria were not fulfilled: minimum genotype quality \>Q40, quality score \>500, strand bias score \<60, and heterozygous read ratio \>60/40.

Odds ratios ([figure 4](#F4){ref-type="fig"}) were calculated for clinical criteria by using standard statistics (χ^2^ test). When data were missing on a patient for a specific clinical criterion, we removed the patient from the analysis and calculated among patients with complete data.

Data availability {#s1-6}
-----------------

Anonymized data will be shared by request from any qualified investigator. When not possible, given the risk to identify rare patients, additional aggregate data in table form will be produced to address specific questions.

Results {#s2}
=======

Diagnoses identified by the 89-gene panel in outpatient clinics {#s2-1}
---------------------------------------------------------------

Samples from a total of 1,236 patients with a suspected muscle disorder were analyzed by gene panel. Adults and children younger than 18 years accounted for 83.7% and 16.3%, respectively. A third of adult patients were aged 60 years and older. Ethnic background was reported to be European non-Finnish in 67.5%, when data were available. Other ethnicities included South and East Asians (14.7%), Mixed Ethnicities (5.1%), Middle East (3.5%), Native Americans and Canadians (3.4%), African Americans (3.2%), Hispanic (1.7%), Ashkenazi Jewish (0.5%), and European Finnish (0.4%). Patients who were recruited from specialized neuromuscular outpatient clinics represented 61.7% of the total cohort, whereas other general neurology, clinical and biochemical genetics, and other clinics accounted for 23.9%, 10.4%, and 4.0%, respectively. More than half of our cohort presented with a limb-girdle weakness, in both children and adults ([figure 1](#F1){ref-type="fig"}).

![Clinical presentation of the pediatric (A) (n = 201) and adult (B) (n = 1,035) cohorts](NG2019011122f1){#F1}

A total of 187 (15.1%) patients had a diagnosis identified ([figure 2](#F2){ref-type="fig"} and table e-2, [links.lww.com/NXG/A235](http://links.lww.com/NXG/A235)), with a diagnostic rate of 22.4% in children and 13.7% in adult patients. A higher diagnostic rate (27.8%) was observed within males of the pediatric cohort due to *DMD*, a gene causing an X-linked disorder. Otherwise, there was not any gender bias. A likely carrier status of a recessive disorder was identified in 9.9%. A potential diagnosis was suspected in 16.4% of the cases ([table 1](#T1){ref-type="table"}). In particular, 66 patients had 2 variants in a gene associated with an autosomal recessive disorder compatible with the patient\'s phenotype, including 33 patients with 1 pathogenic variant and 1 VUS. A biopsy was performed in 18 of 33 patients, of which 17 were abnormal. Among these 17 abnormal biopsies, 14 showed nonspecific findings. Two patients harboring *NEB* variants showed nemaline bodies on muscle biopsy, which supported a diagnosis of nemaline myopathy, but parents were not tested to document whether variants were inherited in trans (patients 336 and 372, see table e-3, [links.lww.com/NXG/A236](http://links.lww.com/NXG/A236)). One patient harboring SGCA variants showed absent alpha-sarcoglycan on muscle biopsy, which supported a diagnosis of autosomal recessive LGMD type 2D, but parents were not tested to document whether variants were inherited in trans (patient 356, see table e-3). Overall, information was insufficient to confirm the diagnosis in these 66 patients. Parental testing and additional specific immunochemistry, when applicable, were therefore recommended.

![Proportion of the confirmed diagnoses (n = 187) and potential diagnoses (n = 202) among our 1,236 patients](NG2019011122f2){#F2}

###### 

Potential diagnoses of our cohort of 1,236 patients

![](NG2019011122t1)

The 187 confirmed diagnoses were distributed across 40 different genes, but 6 explained approximately 50% of all cases ([figure 3C](#F3){ref-type="fig"} and table e-2, [links.lww.com/NXG/A235](http://links.lww.com/NXG/A235)). *DMD* was the most common etiology ([figure 3](#F3){ref-type="fig"}). Among the patients with causal variants in *DMD*, all the 17 adult patients had Becker muscular dystrophy, and 4/11 pediatric patients had Duchenne muscular dystrophy. The latter were all due to a single nucleotide variation (table e-5, [links.lww.com/NXG/A238](http://links.lww.com/NXG/A238)). Half of patients with Becker muscular dystrophy had an exon deletion. Besides *DMD*, the genes most commonly found to be responsible for muscular disease in our cohort were *RYR1, CAPN3*, *PYGM*, *DYSF*, and *FKRP* ([figure 3](#F3){ref-type="fig"}). Among the 187 diagnoses, we identified 248 causal variants: 8.1% were large deletions (exon or whole gene deletion), 23.0% small indels, and 68.9% substitutions. Twenty-six percent of the causal variants are new variants not previously reported (64 variants). Of the 20 large deletions, the majority were hemizygous *DMD* deletions. We also observed 1 heterozygous *KLHL41* whole gene deletion, 1 heterozygous *GAA* whole gene deletion, 2 heterozygous *PYGM* exon deletions, 1 heterozygous *DYSF* exon deletion, and 1 heterozygous *ANO5* exon deletion (table e-2, [links.lww.com/NXG/A235](http://links.lww.com/NXG/A235.)).

![Genes that accounted for the most diagnoses in (A) the pediatric cohort (n = 45), (B) the adult cohort (n = 142), and (C) the whole cohort (n = 187)](NG2019011122f3){#F3}

Clinical characteristics influencing the diagnostic yield {#s2-2}
---------------------------------------------------------

Decreasing diagnostic yield was observed with increasing age, ranging from 22.4% in the 0--17-year-old group, 16.4% between 18 and 59 year olds, and dropping to 9.9% in patients aged 60 years and older. Beside age \<60 years, which was significantly associated with a higher diagnostic yield, other clinical criteria were investigated for their impact on the probability of identifying a molecular diagnosis on the gene panel ([figure 4](#F4){ref-type="fig"}). Notably, the probability was significantly higher in patients having a known cardiac anomaly, a positive family history, or showing elevated CK, and in particular those with CK \> 1,000 IU/L, who showed a diagnostic yield of 24.9%. Among patients with diagnoses, CK value or cardiac information was available on 179 patients, of whom only 10.7% had normal CK value and no cardiac anomaly. There was no significant difference in diagnostic yield between muscle weakness patterns. Finally, although it did not reach statistical significance, the medical specialty of the ordering physician showed some differences in the diagnostic rate: 17.2% (22/128) for geneticists, 17.0% (130/763) for neuromuscular specialists, and 9.5% (28/295) for general neurologists. Other medical specialties accounted for only a small proportion of patients tested (50/1,236), but 7 diagnoses were made among those 50 patients.

![Odds ratios of the different clinical criteria\
Age is separated in 2 categories (\<60 and ≥60 years). Diagnostic yield is higher in patients aged \<60 years. Some values could not be included because the results were not available for all patients (familial history = 938/1,236, creatine kinase \[CK\] = 1,106/1,236, quantitative CK = 642/1,236, EMG = 1,008/1,236, muscle biopsy = 404/1,236, MRI = 146/1,236, respiratory insufficiency = 1,031/1,236, cardiac anomaly = 878/1,236). Error bars represent 95% confidence interval.](NG2019011122f4){#F4}

Diagnostic yield of exome sequencing compared with gene panel {#s2-3}
-------------------------------------------------------------

A total of 46 patients from 1 center were recruited for exome sequencing and analysis of 3,857 mendelian genes (list of genes provided in supplementary files e-2 and e-3, [links.lww.com/NXG/A241](http://links.lww.com/NXG/A241), [links.lww.com/NXG/A242](http://links.lww.com/NXG/A242)). We first analyzed the 89 genes included in the gene panel and identified a diagnosis in 7/46 patients (15.2%). Three additional diagnoses were attributed to genes not included in the muscle disorders 89-gene panel: 1 gene causing metabolic myopathies (*HADHA*), 1 gene causing a mixed nerve and muscle pathology (*MYH14*), and 1 gene associated with oculopharyngeal muscular dystrophy (*PABPN1*). In addition, we identified a homozygous pathogenic variant in *ABCA1* (Tangier disease), but it could not fully account for the patient\'s symptoms (table e-4, [links.lww.com/NXG/A237](http://links.lww.com/NXG/A237)). Another patient was found to harbor a pathogenic variant in *ANO5* along with a variant of unknown significance, but information was insufficient to confirm this potential diagnosis. Overall, the diagnostic rate of exome was increased to 21.7% compared with 15.2% in the (virtual) gene panel for this single center cohort (patients\' details in table e-4).

Although use of exome sequencing could potentially increase the diagnostic rate by analyzing more genes, lower base coverage could lead to missed diagnoses in the 89 genes included in the muscle disorder gene panel. To estimate the proportion of potentially missed diagnoses, we compared the base coverage obtained for these 89 genes from our exome sequencing cohort with the gene panel cohort. On average, the median coverage was 179x (range: 109x--333x) among the 46 patients analyzed by exome sequencing in comparison to 555x (MiSeq, range: 244x--992x) and 1654x (NextSeq, range: 674x--3730x), in 1,236 patients investigated by gene panel according to the sequencing platform used. Among the 3,857 mendelian genes analyzed on exome, 99.61% of bases had adequate coverage as defined by ≥10x. With respect to the 89 genes selected for the muscle disorder gene panel, 99.92% of bases were covered at ≥10x on exome sequencing, similar to what was observed with gene panel on both sequencing platforms (99.92% with MiSeq and 99.95% with NextSeq). Exon 1 of *SELENON* (*SEPN1*) showed poor coverage in both exome and gene panel (irrespective of platform used) in all samples owing to extremely high GC content (86.89%). This exon accounts for ∼0.06% of bases of the 89 muscle disorder genes selected. The small difference in base coverage between exome and gene panel was attributed to some specific exons (mostly GC-rich exons 1) showing recurrent borderline to poor coverage in a minority of patients\' samples (ranging from 2.7% to 36.1%) on exome sequencing: *B3GALNT2* (exon 1), *ISPD* (exon 1), *LMOD3* (exon 1), *PLEC* (exon 1), *SEPN1* (exon 3), *SGCB* (exon 1), *TNNT1* (exons 4 and 5), and *VCP* (exon 1). Likely pathogenic or pathogenic variants (substitutions and indels) have been previously reported in the ClinVar database for 4 of these 8 exons. However, none of the 228 causal substitutions and indels found among the 187 diagnoses on gene panel localized to these exons, and thus, no diagnosis would have been missed. In addition, 14 of the 20 large deletions identified among the 187 diagnoses would probably have been correctly identified by exome sequencing, as they are hemizygous or homozygous. However, the heterozygous exon deletion involving the last 2 exons of *ANO5* could potentially have been missed, as some patients showed base coverage below 50x, which is associated with decreased performance of the CoNVaDING algorithm.^[@R24]^ Notably, this deletion has been identified successfully in another patient on exome sequencing (patient EX11, table e-4, [links.lww.com/NXG/A237](http://links.lww.com/NXG/A237)). The other 5 deletions were all in regions over 100X. At worst, among the patients investigated by gene panel, exome sequencing could have potentially missed 1/248 causal variants (0.4%) or 1 of 187 diagnoses (0.5%).

Discussion {#s3}
==========

Gene panels and exome sequencing are increasingly being used early in the clinical investigation of patients with suspected muscle disorders, evaluated in outpatient clinics. This is likely to be due in part to decreased sequencing cost, improved availability of molecular testing, its less invasive nature compared with muscle biopsy, and some previous studies reporting high diagnostic yield of such approaches in some study populations.^[@R26][@R27][@R28]^ In our study, we report an overall diagnostic yield of 15.1% (22.4% in children and 13.7% in adults) in a large cohort of patients with suspected muscle disorders from outpatient clinics across Canada. Although this is lower than most previous studies,^[@R2][@R3][@R7]^ the present estimation is more likely to be representative of current clinical practice, as it relies on less restrictive criteria for testing (such as previous abnormal muscle biopsy or limb-girdle weakness pattern), does not focus on suspicion of a specific group of disorders (e.g., LGMDs), and involves a large number of different physicians (187) from the common medical specialties involved in the care of patients with suspected muscle disorders: neuromuscular specialists, general neurologists, and geneticists. As expected, the majority of patients (61.7%) were seen by a neuromuscular specialist. The trends suggesting some difference in diagnostic yield between those specialists could either reflect referral bias or more stringent selection of patients for molecular testing.

Our diagnostic yield could be underestimated, as some additional information on patients with potential diagnoses, which represents up to 16.4% of patients, was not readily available to us. In particular, follow-up molecular testing in other family members and detailed muscle biopsy reports could have enabled the reclassification of some VUS as likely pathogenic and led to additional confirmed diagnoses. Thus, the overall diagnostic yield could be as high as 31.5%, but the 15.1% certainly represents a more conservative estimate. Of note, a recent large sequencing effort in the United States involving more than 4,000 patients with a suspected LGMD observed a 27% diagnostic yield with their 35-gene panel.^[@R7]^ The authors included, among the confirmed diagnoses, patients who were compound heterozygotes for a variant of uncertain significance and a likely or pathogenic variant in recessive genes. This contributed to 5.5% of the 27% yield. Similarly, the yield of the present study would have been 17.8% if we had included such patients. Another factor that could have contributed to this relatively lower diagnostic yield is the significant proportion of patients older than 60 years (a third of adult patients). As observed in our study, age \>60 years is associated with a lower diagnostic yield (9.9%). This could be due to an increased contribution of nongenetic disorders in that group.

Similarly to previous studies, we observed a high genetic heterogeneity among diagnoses.^[@R29][@R30][@R32]^ Of interest, the genes most commonly represented among the confirmed diagnoses were similar between children and adults, with *DMD*, *RYR1, CAPN3*, *PYGM*, *DYSF*, and *FKRP* accounting for 50% and 58% of diagnoses in children and adults, respectively. The previous large LGMD US study identified *CAPN3, DYSF*, and FKRP as the 3 major contributing genes, associated with 17%, 16%, and 9% of diagnoses, respectively, but *DMD* was only found in 4%, whereas *RYR1* and *PYGM* were not tested.^[@R7]^

In our study, variants in *DMD* were the most frequent cause identified on gene panel in both age groups. This relatively high proportion might reflect some differences between our cohort and other published cohorts as regards prior molecular testing to rule out *DMD* pathogenic variants when there was a clinical suspicion of Duchenne or Becker dystrophy. We did not require that *DMD* deletions/duplications be ruled out by specific testing prior performing the gene panel. Despite the wide availability of multiplex ligation-dependent probe amplification-based deletion and duplication analysis across Canada, a total of 12 of 28 causal variants identified in *DMD* were deletions of one or multiple exons. We suspect that a change in clinical practice might have occurred among the users of our gene panel as a result of its easy access and its ability to identify virtually all *DMD* variants in males. This would have led to a decrease in the use of MLPA-based deletion and duplication analysis and an increase in the proportion of *DMD* cases identified by the 89-gene panel. With decreasing cost of gene panel and easier availability, this tendency could occur in other countries as well.

However, all exon deletions were observed in patients with Becker muscular dystrophy and not in patients with Duchenne muscular dystrophy, which may be related to the more variable phenotype of Becker muscular dystrophy. When detailed phenotypic data were available, we could observe suggestive evidence in some patients that atypical clinical presentation likely contributed to the decision not to request *DMD* MLPA, leading to an increased prevalence of deletions observed in our cohort. For instance, there was a 68-year-old male patient with mild limb-girdle and distal weakness and negative family history (patient 52 on table e-2, [links.lww.com/NXG/A235](http://links.lww.com/NXG/A235)) and two 11-year-old twins with predominant distal weakness (patients 77--78 on table e-2; elevated CK 560--1,100 IU/L, no muscle biopsy performed). Another male patient, in whom a *DMD* deletion was subsequently identified, presented initially with polyhydramnios and neonatal hypotonia. At age 13 years, he was reported to show diffuse weakness, decreased muscle bulk, and negative family history (patient 2 on table e-2; elevated CK 950 IU/L, no biopsy available). In particular, in this last case, a variant in a second gene (or an additional nongenetic disorder) likely contributed to the atypical phenotype.

Finally, the fact that *DMD* sequencing is not easily accessible in some Canadian provinces and requires special approval processes that may limit access in some cases may have contributed to an increased proportion of DMD cases in our cohort. Supporting this, all patients diagnosed with Duchenne muscular dystrophy were caused by single nucleotide variation. Those patients are expected to be recognized on a clinical basis, and thus would likely not be sent for gene panel if DMD sequencing was more accessible in some Canadian provinces. This factor presumably contributed to increase the proportion of causal *DMD* variants observed, especially in the pediatric group compared with other countries having easier access to *DMD* sequencing. Nevertheless, even if we exclude patients with Duchenne muscular dystrophy, variants in *DMD* would remain the most common cause of muscle disorders identified in the pediatric group.

We investigated whether any clinical criteria could be used to select patients who would more likely benefit from gene panel testing while having minimal risk of missing a diagnosis. As expected, positive family history and younger age were correlated with an increased likelihood of finding a genetic etiology, but the yield remained significant in patients older than 60 years (9.9%). We had to use age at testing as a proxy for age at onset because accurate historical information was not systematically available. Other criteria that were associated with increased diagnostic yield were high serum CK (especially if above 1,000 IU/L), the presence of a cardiac anomaly, and a positive familial history. These likely reflect better diagnostic yield in muscular dystrophies.^[@R31],[@R33],[@R34]^ Nevertheless, excluding patients with normal CK results and no cardiac anomaly from testing would have resulted in missing 10.7% of the diagnoses, including 3/6 patients with *MYOT* causal variants who were aged \>55 years. Some other patients with such conditions may have been excluded from testing by our protocol, which required 1 abnormal laboratory for testing to be performed. Evaluation of more patients would be needed to analyze the impacts of more complex combinations of clinical criteria.

Finally, with decreasing sequencing cost, many clinical laboratories are considering moving to larger sequencers that would enable analysis of exome-based virtual panels instead of gene panels. Both methods have their advantages and limitations (table e-6, [links.lww.com/NXG/A239](http://links.lww.com/NXG/A239)). In our study, we investigated how this applies in the context of suspected muscle disorders and the genes that were included in our analysis. First, there was only minimal difference (0.03%) in terms of percentage of bases with adequate coverage (\>10x), even if median coverage was more than 3--10 times higher for gene panel (depending on the sequencing platform used) compared with exome-based virtual panel. In a minority of patients\' samples analyzed by exome, some exons showed borderline or low coverage that could impede detection of single nucleotide variations or indels, although it would not be expected to affect significantly the diagnostic yield based on causal variants found in the gene panel cohort. Moreover, detection of large heterozygous deletions and duplications could be limited by lower coverage of the exome-based panel, especially when dropping below 50x.^[@R24]^ Nonetheless, even with optimal coverage, detection of small exon deletions (\<3 exons) remains challenging.^[@R35],[@R36]^ This applies to *DMD* heterozygous deletions in female and duplications in both male and female. In our study, we did not systematically study the performance of both MLPA and next-generation sequencing method to detect those variants. As deletions and duplications remain a rare type of causal variant, apart from the X-linked *DMD* gene exon deletions that can still be detected with decreasing coverage in males, the impact on the diagnostic yield would have been limited. Still, it would have possibly resulted in 1 missed diagnosis (1/187, 0.5%). This emphasizes the need to carefully validate each virtual gene panel to ensure sufficient coverage to detect all variant types with optimal performance. Alternatively, performing additional deletion analysis in parallel by exon array or MLPA for specific genes could be recommended when a single pathogenic variant is found or for *DMD* in all cases. Nevertheless, despite these limitations, our study shows that an exome-based panel with analysis extended to other mendelian genes increased the diagnostic yield from 15.2% to 21.7% in the exome cohort. On patients selected with the same criteria, the 3 additional diagnoses emphasize the fact that all gene panel designs are subject to omission of genes that may represent more atypical cause of weakness (*HADHA*), the difficulty sometimes encountered in differentiating myopathic from neuropathic pathologies on a clinical basis (*MYH14*), and accuracy for triplet repeats might be limited for next-generation sequencing compared with PCR (*PABPN1*).^[@R43]^ In particular, our panel did not provide comprehensive coverage of metabolic myopathies, given that the primary indication of our panel was weakness and not rhabdomyolysis. It is not possible to transpose and generalize this increase of diagnostic yield to the group of patients recruited from various Canadian outpatient clinics (cohort of 1,236 patients), although overall diagnostic yield of the 89 genes is similar between the 2 groups of patients studied (15.1% and 15.2%). Various bias could influence the proportion of cases harbouring variants in genes outside the 89-gene panel. This includes a different population of recruiting physicians with different level of expertise in muscle disorders and a different proportion of abnormal muscle biopsies or prior negative genetic tests, which are both not accurately known in the cohort of 1,236 patients. We also observed a modest increase of variants of uncertain clinical significance related to patient phenotype when extending the analysis beyond the virtual 89-gene panel. However, we were quite conservative in reporting and had access to the complete patient file in the exome cohort. The number of VUS might be much more increased in the regular laboratory setting with limited clinical information. Overall, our results support the use of an exome-based panel for muscular disorders, although several considerations must be taken into account when introducing exome-based panel in the laboratory^[@R38][@R39][@R40]^ (table e-6, [links.lww.com/NXG/A239](http://links.lww.com/NXG/A239)).

Establishing a molecular diagnosis in patients with muscle disorders is becoming increasingly important, as the potential to alter the disease course with gene specific treatments is expected to increase in the upcoming years. Specific treatments are currently limited for hereditary muscle disorders, and enzyme replacement therapy represents 1 example. However, gene therapy approaches are undergoing rapid development for the treatment of LGMDs and dystrophinopathies, in particular. Indeed, several studies are in clinical trials and have shown the potential of this method.^[@R41][@R42][@R46]^ This shows the importance of having a diagnosis for these patients.

Our study supports the use of gene panel testing in patients with suspected muscle disorders from outpatient clinics and highlights several relatively common diagnoses identified in adults and children (*DMD, RYR1, CAPN3, PYGM, DYSF,* and *FKRP*). Moreover, it shows that exome sequencing has a low risk of missing diagnoses compared with gene panel, while potentially increasing the diagnostic yield of patients with muscle disorders. However, exome sequencing comes with a bigger burden of VUS. It would though be important, with an exome approach, to have elaborated clinical data and to have the data analyzed in a center experimented in variant interpretation in neuromuscular conditions. Combining MLPA-based deletion and duplication analysis for *DMD* with 1 of the 2 sequencing methods could result in a higher accuracy for Duchenne and Becker muscular dystrophies, especially in females, given lower sensibility for small heterozygous exon deletions.
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